Parkman Healthcare Partners LLC Oncternal Therapeutics, Inc. Transaction History

Parkman Healthcare Partners LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$1.37 - $2.43 $396,313 - $702,950	-289,280 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$2.27 - $4.39 $81,956 - $158,496	-36,104 Reduced 11.1%	289,280 $657,000
Q3 2021 Nov 12, 2021	SELL	$3.37 - $4.76 $303,300 - $428,400	-90,000 Reduced 21.67%	325,384 $1.36 Million
Q2 2021 Aug 13, 2021	SELL	$4.75 - $9.39 $1.73 Million - $3.41 Million	-363,401 Reduced 46.66%	415,384 $1.97 Million
Q1 2021 May 14, 2021	BUY	$4.59 - $9.04 $1.85 Million - $3.63 Million	402,006 Added 106.7%	778,785 $6.48 Million
Q4 2020 Feb 12, 2021	BUY	$1.51 - $6.3 $568,936 - $2.37 Million	376,779 New	376,779 $1.85 Million

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.